{
  "id": 19846620,
  "title": "Final trial results show promising long-term survival with lenvatinib plus pembrolizumab in advanced thymic tumors",
  "url": "https://urgent.news/2026/11/13/final-trial-results-show-promising-long-term-survival-with-lenvatinib",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-13T18:20:07.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-11-trial-results-term-survival-lenvatinib.html"
  },
  "original_language": "en",
  "account": "Recent trial findings suggest a promising combination of lenvatinib and pembrolizumab may offer long-term survival benefits for patients with advanced thymic tumors after initial platinum-based chemotherapy. The phase 2 PECATI trial, published in the Journal of Thoracic Oncology, detailed 40.2 months median overall survival and 22.1 months median progression-free survival, with 44.2% of the 43 participants experiencing grade 3 or higher adverse events.",
  "summary": "Final results from the phase 2 PECATI clinical trial demonstrate encouraging long-term survival outcomes with the combination of lenvatinib and pembrolizumab in patients with previously treated advanced B3-thymoma and thymic carcinoma.",
  "key_points": [
    "Lenvatinib and pembrolizumab combination shows long-term survival promise",
    "PECATI trial reveals 40.2 months median overall survival",
    "44.2% of participants experienced grade 3+ adverse events"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}